Arginetix-Immune Control merger targets pulmonary, vascular disorders
This article was originally published in Scrip
Executive Summary
Arginetix, the Baltimore-based biopharmaceutical company developing small-molecule inhibitors of the enzyme arginase (scripnews.com, 7 October 2009), has broadened its technology base and strengthened its human resources by merging with Immune Control, a spin-off from Drexel University College of Medicine in Philadelphia.